Published in Vaccine Weekly, March 22nd, 2000
Thomas Kosten, MD, principal investigator on the Phase 1 study, and his team administered the vaccine to 34 former cocaine abusers living in a residential treatment facility.
The vaccine, TA-CD, is designed to generate drug-specific antibodies, which bind to cocaine and prevent it from traveling to the brain from the bloodstream. This neutralizes its psychoactive effect.
"The vaccine is very safe and we did not observe any major side effects," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2000-03-22)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.